Background

Malaria is a devastating disease that continues to plague many regions of the world, particularly in Africa. Transmitted by mosquitoes, malaria parasites can cause severe illness and even death. In 2015 alone, an estimated 429,000 people died from malaria, 92% of whom were in Africa.

RTS,S: The First Malaria Vaccine

In a significant development in the global fight against malaria, the World Health Organization (WHO) has selected Kenya, Ghana, and Malawi to pilot the world’s first malaria vaccine, RTS,S. The vaccine was developed in collaboration between PATH and GlaxoSmithKline, with support from the Bill and Melinda Gates Foundation.

Pilot Program

The pilot program, scheduled to begin in 2018, aims to test the feasibility and effectiveness of delivering the RTS,S vaccine to children in the target countries. At least 120,000 children between the ages of five and 17 months will receive the vaccine in each country. The goal is to determine whether the vaccine can be successfully implemented and whether it can help reduce the incidence of malaria.

Challenges and Efficacy

While the prospect of a malaria vaccine is promising, it is important to acknowledge the challenges and limitations associated with its development. The vaccine has shown varying levels of efficacy in different studies. In a 2015 study, researchers found that the vaccine was less effective than expected and required multiple doses.

A follow-up study in 2016 revealed that the vaccine had “negative efficacy” five years after the first dose in children living in areas with high exposure to malaria-carrying mosquitoes. This suggests that the vaccine may only delay malaria rather than preventing it altogether.

To address these concerns, the pilot program will administer four doses of the vaccine instead of three. However, each additional dose poses logistical challenges in ensuring that children receive all the necessary vaccinations.

Evolving Mosquitoes and Resistance

Another challenge to malaria control is the evolution of mosquitoes that are becoming more resistant to insecticides. This resistance can reduce the effectiveness of insecticide-treated nets, a key preventive measure against malaria.

Despite these challenges, the development and testing of new malaria vaccines remains crucial. Each new tool in the arsenal against malaria increases the chances of eventually eliminating the disease.

Role of the WHO and Other Organizations

The WHO plays a pivotal role in coordinating global efforts to combat malaria. The organization sets guidelines and standards for malaria control and supports research and development of new vaccines and treatments.

PATH, GlaxoSmithKline, and the Bill and Melinda Gates Foundation are among the key organizations involved in the development and testing of the RTS,S vaccine. These organizations provide funding, expertise, and logistical support for research and implementation.

Conclusion

The pilot program for the RTS,S malaria vaccine is a significant step towards finding new and effective ways to combat this deadly disease. While challenges remain, the development of new vaccines and the continued efforts of international organizations offer hope for a future free from malaria.

Development Challenges

Developing a malaria vaccine has been an arduous journey due to the complexity of the malaria parasite. The parasite has a unique life cycle and can evade the immune system. Early attempts to create a vaccine based on the circumsporozoite protein failed, but RTS,S emerged as a promising candidate.

Lack of Urgency and Funding

Despite its potential, the development of RTS,S faced significant obstacles. There was a lack of urgency and funding for malaria research, as it primarily affects impoverished regions of Africa. The military, which had initially shown interest in a vaccine, later withdrew its support.

Logistical Hurdles

Testing the vaccine in African countries proved to be challenging. Researchers faced logistical issues such as establishing laboratories and conducting trials in young children. The process took over 10 years to complete.

Safety Concerns and Expanded Trials

Phase III trials showed promising results, but concerns about meningitis and death in vaccinated girls led the WHO to request a larger trial. This resulted in a four-year delay and further setbacks in manufacturing.

Approval and Rollout

After reviewing the expanded trial data, the WHO finally recommended RTS,S for widespread use in 2021. GAVI, a global vaccine distribution agency, announced an investment of $155.7 million for rollout.

Comparison with COVID-19 Vaccine Development

The rapid development of COVID-19 vaccines has raised questions about why a malaria vaccine took so long. Experts note that malaria is a more difficult target for a vaccine, and that the lower efficacy of RTS,S may have slowed down the process. Additionally, existing antimalarial tools have reduced the perceived urgency for a vaccine.

Disparities in Funding and Attention

The disparity in funding and attention between malaria and COVID-19 highlights longstanding patterns of neglect for diseases that primarily affect low-income countries. Funding for malaria vaccine research has been declining, posing a risk to the rollout of RTS,S.

Next-Generation Vaccines

RTS,S has paved the way for next-generation malaria vaccines. The University of Oxford’s R21 vaccine is showing promise in Phase II trials. BioNTech, the company behind the mRNA COVID-19 vaccine, is also developing a malaria vaccine using the same technology.

Future Outlook

Experts are optimistic that future malaria vaccines will be developed more quickly and effectively. Advances in mRNA technology and other innovations could lead to game-changing breakthroughs.

Background

Malaria, a mosquito-borne disease, remains a significant threat, particularly in Africa, where it claims the life of a child every minute. Scientists and public health officials have made progress in combating malaria, but the search for an effective vaccine has been ongoing.

Mosquirix: The First Malaria Vaccine

The pharmaceutical company GlaxoSmithKline, with funding from the Bill and Melinda Gates Foundation, has developed a vaccine called Mosquirix (RTS,S), which has recently passed a major regulatory hurdle. The European Medicines Agency (EMA) has recommended the vaccine as safe and effective for use in at-risk babies in Africa.

Efficacy and Challenges

While the approval of Mosquirix is a significant step forward, it is important to note that the vaccine is not as effective as initially hoped. In a large clinical trial, it reduced malaria episodes by about one-third in young children in sub-Saharan Africa, falling short of the 50% efficacy target and far from the 95% efficacy typically desired for vaccines.

Additionally, Mosquirix requires three doses to be administered to babies. Over time, its effectiveness wanes, necessitating a booster dose. These factors raise concerns about the cost-benefit analysis of the vaccine, particularly in resource-limited settings.

Weighing the Risks and Benefits

Despite the limitations, the EMA has determined that the benefits of Mosquirix outweigh the risks. The vaccine is the most advanced in development, and GlaxoSmithKline is already working on a second-generation version.

Experts acknowledge that even a partially effective vaccine could have a significant impact in reducing the burden of malaria. For children who experience multiple severe malaria episodes annually, the vaccine could potentially transform their lives.

Next Steps

The World Health Organization (WHO) will now decide whether to recommend the use of Mosquirix and provide guidance on its implementation. Individual countries will then make their own decisions on whether to adopt the vaccine.

Progress and the Future

While Mosquirix is not a perfect vaccine, it represents a significant milestone in the fight against malaria. GlaxoSmithKline’s ongoing research and development efforts hold promise for the future development of more effective and convenient malaria vaccines.

If the approval process proceeds smoothly, the first doses of Mosquirix could be available to babies in 2017, offering new hope in the fight against this devastating disease.

A team of engineers at the University of California, Berkeley, has developed a smartphone microscope called CellScope that can detect parasites in blood samples in just minutes. This breakthrough could revolutionize the diagnosis of neglected tropical diseases such as onchocerciasis and lymphatic filariasis, which affect millions of people in developing countries.

How CellScope Works

CellScope is a small, portable device that attaches to a smartphone. It uses a combination of LED lights, microcontrollers, and a USB port to process blood samples. The phone’s camera then takes a series of videos of the blood sample, which are analyzed by an algorithm to detect the movement of parasites.

Unlike traditional Loa loa diagnosis, which requires a lab and a trained technician, CellScope can be used by anyone, anywhere. This is especially important in rural areas where access to conventional medical care is limited.

Benefits of CellScope

CellScope offers several benefits over traditional diagnostic methods:

• Fast: CellScope can provide results in less than 3 minutes, compared to days for traditional methods.
• Accurate: CellScope’s algorithm is highly accurate at detecting parasites, even in low concentrations.
• Portable: CellScope is small and lightweight, making it easy to transport to remote areas.
• Affordable: CellScope is relatively inexpensive to produce, making it accessible to communities with limited resources.

Applications of CellScope

CellScope has the potential to be used for a variety of applications, including:

• Diagnosing neglected tropical diseases: CellScope can be used to diagnose onchocerciasis, lymphatic filariasis, and other neglected tropical diseases that are transmitted by parasites.
• Detecting Loa loa infection: CellScope can detect Loa loa infection, which can be fatal if treated with ivermectin, a drug used to treat onchocerciasis and lymphatic filariasis.
• Diagnosing non-parasitic diseases: CellScope could also be used to diagnose non-parasitic diseases, such as tuberculosis, in areas where traditional microscopes are scarce.

Future of CellScope

The developers of CellScope hope to expand its use to diagnose other diseases and to make it even more affordable and accessible. They are also working on developing a version of CellScope that can be used to diagnose diseases in animals.

CellScope has the potential to revolutionize the diagnosis of infectious diseases in developing countries. Its speed, accuracy, portability, and affordability make it an ideal tool for improving global health.

Additional Information

• CellScope website
• Video: How CellScope works
• Article: CellScope: A smartphone microscope for diagnosing neglected tropical diseases